Glaxis Capital Management’s Medtronic MDT Stock Holding History

Glaxis Capital Management’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,000	Closed	-$622K	–	16
2022 Q4	$622K	Hold	8,000	–	–	8.42%	5
2022 Q3	$646K	Hold	8,000	–	–	9.34%	3
2022 Q2	$718K	Hold	8,000	–	–	10.95%	2
2022 Q1	$888K	Buy	+8,000	New	+$845K	1.25%	14

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Glaxis Capital Management's MDT Position: Q1 2023 in Review

Glaxis Capital Management sold out of Medtronic (MDT) in Q1 2023, closing a stake of 8,000 shares — an estimated $622K sold.

Glaxis Capital Management first reported a position in MDT in Q1 2022 and held it in 4 quarters. The position peaked at $888K in Q1 2022. 1,991 funds tracked by Wall St. Rank hold MDT as of Q1 2023.

Glaxis Capital Management reported no remaining Medtronic position as of Q1 2023 after selling out during the quarter.
Glaxis Capital Management sold 8,000 Medtronic shares in Q1 2023, an estimated $622K.
Glaxis Capital Management first reported a position in Medtronic in Q1 2022 and held it in 4 quarters.
Glaxis Capital Management's Medtronic position peaked at $888K in Q1 2022.
1,991 funds tracked by Wall St. Rank held Medtronic as of Q1 2023.

Based on Glaxis Capital Management's 13F filing for Q1 2023, filed 9 May 2023.